Publications by authors named "Pu-Chun Li"
Long-term survival varies among hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer patients and is seriously impaired by metastasis. Chromosomal instability (CIN) was one of the key drivers of breast cancer metastasis. Here we evaluate CIN and 10-year invasive disease-free survival (iDFS) and overall survival (OS) in HR+/HER2-- breast cancer.
View Article and Find Full Text PDFPurpose: Our study aimed to develop and validate a homologous recombination deficiency (HRD) scoring algorithm in the Chinese breast cancer population.
Methods And Materials: Ninety-six in-house breast cancer (BC) samples and 6 HRD-positive standard cells were analyzed by whole-genome sequencing (WGS). Besides, 122 BCs from the TCGA database were down-sampled to ~ 1X WGS.
Article Synopsis
- This study investigates the role of mutations in breast cancer patients in China, particularly focusing on hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative cases.
- Out of 629 women diagnosed with breast cancer, 78 (12.4%) had mutations, which were linked to lower average age at diagnosis and higher rates of lymph node positivity compared to non-mutation cases.
- Findings indicate that while mutation breast cancers had some adverse characteristics, such as a higher prevalence of familial breast and ovarian cancer history, mutations did not significantly impact invasive disease-free survival or distant relapse-free survival.
Article Synopsis
- - BRCA2 mutation carriers face a significant lifetime risk for breast cancer, often developing it at a younger age and having heightened susceptibility to several other cancers.
- - A large majority (70-80%) of breast cancers in BRCA2 mutation carriers are classified as estrogen receptor (ER)-positive, which differs from the typical ER-positive breast cancer seen in the general population.
- - The article examines the clinical features, treatment options, and prognosis of ER-positive breast cancer in BRCA2 mutation carriers to aid in making informed clinical decisions.
A comprehensive analysis of Fanconi anemia genes in Chinese patients with high-risk hereditary breast cancer.
J Cancer Res Clin Oncol
November 2023
Article Synopsis
- - The study examined the role of 16 Fanconi anemia (FA) genes in breast cancer (BC) among 1481 high-risk hereditary BC patients in China, identifying 38 patients with mutations in these genes, mainly FANCA.
- - Findings indicated that FA gene mutation carriers had worse clinicopathological features, including higher tumor sizes and lower survival rates compared to non-carriers, along with significant differences in lymph node status.
- - The research suggests that specific FA gene mutations may contribute to breast cancer risk, and further exploration is warranted to better understand their implications in various populations.
A clinically useful immune biomarker could potentially assist clinicians in their decision making. We stimulated T-cell proliferation to secret interferon gamma (IFN-γ) by phytohemagglutinin, and then measured the production of IFN-γ (mitogen value [M value]). We aimed to determine the relationship between the M value, clinical severity, and outcomes of diseases.
View Article and Find Full Text PDF